ValuEngine downgraded shares of MOTIF BIO PLC/S (NASDAQ:MTFB) from a buy rating to a hold rating in a report released on Wednesday morning.

Separately, HC Wainwright set a $32.00 price objective on MOTIF BIO PLC/S and gave the company a buy rating in a research note on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $19.50.

MTFB stock opened at $7.90 on Wednesday. MOTIF BIO PLC/S has a 1-year low of $7.33 and a 1-year high of $13.75. The company has a debt-to-equity ratio of -1.58, a quick ratio of 0.96 and a current ratio of 0.96.

About MOTIF BIO PLC/S

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Featured Story: Understanding Average Daily Trade Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MOTIF BIO PLC/S (NASDAQ:MTFB)

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.